Childrens Mercy Hospital
- Type
- Teaching hospital
- Where
- Kanas City, MO
- Medicare CCN
- 263302
- Received
- $3,026,113 in 949 records, 2023 ($503,418 general, $2,522,694 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE CHILDRENS MERCY HOSPITAL CORPORATION Fuzzy (name and state)
- Federal award recipient: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
- Nonprofit: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 29 | $503,418 |
| 2023 | Research payment | 920 | $2,522,694 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 920 | $2,522,694 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 10 | $481,759 |
| Long term medical supply or device loan | 9 | $13,235 |
| Consulting Fee | 6 | $4,650 |
| Debt forgiveness | 2 | $2,574 |
| Space rental or facility fees (teaching hospital only) | 2 | $1,200 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Stryker Corporation | $11,200 | Long term medical supply or device loan | In-kind items and services | UNIVERSAL NEURO 2, UNIVERSAL NEURO III Device, NEURO SPINE ENT | 2023 | |
| 2023-12-31 | Linvatec Corporation | $1,273 | Long term medical supply or device loan | In-kind items and services | HANDSTAND Device, ORTHOPEDIC SURGERY | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $281 | Research payment | In-kind items and services | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2023 |
| 2023-12-31 | Stryker Corporation | $212 | Long term medical supply or device loan | In-kind items and services | SONOPET IQ Device, NEURO SPINE ENT | 2023 | |
| 2023-12-31 | Stryker Corporation | $100 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $100 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $100 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $100 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $78 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous IV and Powder for Oral Suspension Formulations | 2023 |
| 2023-12-31 | Stryker Corporation | $72 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Stryker Corporation | $72 | Long term medical supply or device loan | In-kind items and services | REMB Device, SURGICAL | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $38 | Research payment | Cash or cash equivalent | JANUVIA Drug, ENDOCRINOLOGY | A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficac | 2023 |
| 2023-12-28 | Streck LLC | $330 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-27 | ALBIREO PHARMA, INC. | $1,751 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2023 |
| 2023-12-27 | PFIZER INC. | $526 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-12-22 | Abbott Laboratories | $9,129 | Research payment | Cash or cash equivalent | FreeStyle Libre 2 Device, Diabetes Care | FreeStyle Libre 2 Flash Glucose Monitoring System Intervention Phase Study | 2023 |
| 2023-12-21 | ALBIREO PHARMA, INC. | $5,582 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2023 |
| 2023-12-21 | ALBIREO PHARMA, INC. | $5,000 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2023 |
| 2023-12-19 | AstraZeneca UK Limited | $25,850 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | Multicentre,Randomised,Double blind,Parallel Group,Placebo controlled,Time to first Asthma Exacerbation Phase tree Effic | 2023 |
| 2023-12-19 | HEMA Biologics, LLC | $3,000 | Research payment | Cash or cash equivalent | SevenFact Biological, Hematology | ATHN 16 | 2023 |
| 2023-12-19 | HEMA Biologics, LLC | $3,000 | Research payment | Cash or cash equivalent | SevenFact Biological, Hematology | ATHN 16 | 2023 |
| 2023-12-19 | Ultragenyx Pharmaceutical Inc. | $2,342 | Research payment | Cash or cash equivalent | UX143-CL301 | 2023 | |
| 2023-12-18 | Novo Nordisk AS | $1,080 | Research payment | Cash or cash equivalent | NN7415-4807 | 2023 | |
| 2023-12-18 | Travere Therapeutics, Inc. | $90 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2023 | |
| 2023-12-14 | Edwards Lifesciences Corporation | $17,508 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2023 |
| 2023-12-14 | Edwards Lifesciences Corporation | $9,832 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2023 |
| 2023-12-14 | Edwards Lifesciences Corporation | $284 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2023 |
| 2023-12-13 | E.R. Squibb & Sons, L.L.C. | $5,000 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIA Nivo in HL Pediatric (nivo+bv) - A Phase I/II Trial of Nivolumab Plus Ipilimumab in Children and Young Adults | 2023 |
| 2023-12-12 | Ultragenyx Pharmaceutical Inc. | $1,624 | Research payment | Cash or cash equivalent | UX143-CL301 | 2023 | |
| 2023-12-11 | Immedica Pharma US, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Comp | 2023 | |
| 2023-12-07 | Edwards Lifesciences Corporation | $3,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2023 |
| 2023-12-06 | Merck Sharp & Dohme LLC | $89,562 | Research payment | Cash or cash equivalent | PNEUMOVAX 23 Biological, VACCINE | Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients | 2023 |
| 2023-12-05 | Bayer Healthcare Pharmaceuticals Inc. | $3,600 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | Finerenone paediatric CKD trial | 2023 |
| 2023-11-30 | Ultragenyx Pharmaceutical Inc. | $1,955 | Research payment | Cash or cash equivalent | UX143-CL301 | 2023 | |
| 2023-11-28 | Ultragenyx Pharmaceutical Inc. | $12,250 | Research payment | Cash or cash equivalent | UX143-CL301 | 2023 | |
| 2023-11-27 | Rhythm Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-035 | 2023 |
| 2023-11-27 | Rhythm Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-035 | 2023 |
| 2023-11-27 | Rhythm Pharmaceuticals, Inc. | $750 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-035 | 2023 |
| 2023-11-27 | Novo Nordisk AS | $720 | Research payment | Cash or cash equivalent | NN7415-4807 | 2023 | |
| 2023-11-27 | Rhythm Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-035 | 2023 |
| 2023-11-27 | Rhythm Pharmaceuticals, Inc. | $350 | Research payment | Cash or cash equivalent | Imcivree Drug, Genetic Disease | RM-493-035 | 2023 |
| 2023-11-22 | Edwards Lifesciences Corporation | $5,967 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2023 |
| 2023-11-22 | Edwards Lifesciences Corporation | $5,200 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2023 |
| 2023-11-22 | Travere Therapeutics, Inc. | $2,306 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2023 | |
| 2023-11-22 | Novo Nordisk AS | $630 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2023 |
| 2023-11-22 | Edwards Lifesciences Corporation | $568 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2023 |
| 2023-11-22 | Edwards Lifesciences Corporation | $450 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2023 |
| 2023-11-22 | Edwards Lifesciences Corporation | $408 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2023 |
| 2023-11-22 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2023 |
| 2023-11-21 | Gilead Sciences, Inc. | $2,924 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2023 |
| 2023-11-21 | Ultragenyx Pharmaceutical Inc. | $1,064 | Research payment | Cash or cash equivalent | UX143-CL301 | 2023 | |
| 2023-11-21 | Ultragenyx Pharmaceutical Inc. | $358 | Research payment | Cash or cash equivalent | UX143-CL301 | 2023 | |
| 2023-11-21 | Travere Therapeutics, Inc. | $70 | Research payment | Cash or cash equivalent | 021IGAN17001 | 2023 | |
| 2023-11-20 | Travere Therapeutics, Inc. | $3,390 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2023 | |
| 2023-11-20 | Travere Therapeutics, Inc. | $875 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Tre | 2023 | |
| 2023-11-15 | Gen-Probe, Inc. | $175,195 | Research payment | Cash or cash equivalent | PANTHER FUSION Device, Diagnostics | Comparison of nasal swab and nasopharyngeal swab for respiratory testing using Hologic Panther Fusion assay | 2023 |
| 2023-11-15 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | DALVANCE Drug, ANTI-INFECTIVE | Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to b | 2023 |
| 2023-11-10 | QOL Medical, LLC | $500 | Research payment | Cash or cash equivalent | Sucraid Drug, THERAPY FOR CSID | QOL Pediatric Sucraid | 2023 |
| 2023-11-09 | Astellas Pharma Global Development | $315 | Research payment | Cash or cash equivalent | Cresemba Drug, Infectious Diseases | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2023 |
| 2023-11-08 | PFIZER INC. | $117 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-11-06 | Edwards Lifesciences Corporation | $13,724 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2023 |
| 2023-11-06 | Ultragenyx Pharmaceutical Inc. | $12,536 | Research payment | Cash or cash equivalent | UX143-CL301 | 2023 | |
| 2023-11-06 | Edwards Lifesciences Corporation | $2,000 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2023 |
| 2023-11-06 | Edwards Lifesciences Corporation | $408 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | ALTERRA Post-Approval Study 2021-11 | 2023 |
| 2023-11-06 | Edwards Lifesciences Corporation | $354 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | COMPASSION S3 Post Approval Study (2020-07) | 2023 |
| 2023-11-02 | Astellas Pharma Global Development | $2,130 | Research payment | Cash or cash equivalent | Cresemba Drug, Infectious Diseases | A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmaco | 2023 |
| 2023-11-02 | ALBIREO PHARMA, INC. | $1,400 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2023 |
| 2023-11-02 | ALBIREO PHARMA, INC. | $1,300 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Childr | 2023 |
| 2023-11-02 | ALBIREO PHARMA, INC. | $525 | Research payment | Cash or cash equivalent | Bylvay Drug, Gastroenterology | An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndro | 2023 |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 | |
| 2023-10-31 | Novo Nordisk AS | $3 | Research payment | In-kind items and services | NN7415-4807 | 2023 |
The latest 200 records of 949.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
In Missouri; placed by its state only.
| Measure | State Missouri |
|---|---|
| Population B01003 | 6,191,814 |
| Population, 2020 census P1 | 6,154,913 |
| Median age B01002 | 39.0 |
| Under 18 B01001 | 22.3% |
| 65 and over B01001 | 17.9% |
| Households B11001 | 2,508,227 |
| Foreign born B05002 | 4.5% |
| Median household income B19013 | $70,702 |
| Median family income B19113 | $91,360 |
| Per capita income B19301 | $39,695 |
| Poverty rate B17001 | 12.6% |
| Unemployment rate B23025 | 4.0% |
| Civilian labor force B23025 | 3,120,639 |
| Mean commute (minutes) B08013 | 23.5 |
| Bachelor's degree or higher B15003 | 32.4% |
| Housing units B25001 | 2,825,287 |
| Owner-occupied B25003 | 68.1% |
| Renters B25003 | 31.9% |
| Median home value B25077 | $230,300 |
| Median gross rent B25064 | $1,033 |
| White, not Hispanic B03002 | 76.3% |
| Black B03002 | 10.9% |
| Hispanic or Latino B03002 | 5.2% |
| Asian B03002 | 2.1% |
| American Indian and Alaska Native B03002 | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Missouri.
Comments